Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Landmark research suggests the appetite-suppressing jabs which mimic a hormone that makes us feel full also significantly cut ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Doctors prescribe Wegovy for people with obesity or overweight and at least one related condition. It helps suppress appetite, aiding weight management. Wegovy has recently become very popular ...

As the use of GLP-1s soars in popularity, diners are wrestling with new restaurant etiquette dilemmas — and adjusting ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Newer medications, such as Mounjaro and Wegovy, exhibit both more total weight lost and faster weight regain than older medications Montinique Monroe/Bloomberg via Getty A new analysis determined ...